CFDE Data Portal | Search PCDHB1-AS1

	Label	Description
	PCDHB1-AS1 Gene (Entity type)	ENSG00000279047 - PCDHB1 antisense RNA 1
	GSE111247 temozolomide LN-308 14 v 12 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE162892 ISOX 3 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE214931 temozolomide 4 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE206931 WDR5 inhibition WIN 3 v 6 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE119978,GSE180930 0 V 4 CISPLATIN HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE56010 adenosine 4 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE158834 ADIPOR2 knockout HEK293 12 v 13 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE157960 0 V 3 PROGESTERONE MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE152699 GSE152723 vemurafenib 3 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS

PCDHB1-AS1

ENSG00000279047 - PCDHB1 antisense RNA 1

GSE111247 temozolomide LN-308 14 v 12 human dn

A Gene Set from LINCS

GSE162892 ISOX 3 v 2 human dn

A Gene Set from LINCS

GSE214931 temozolomide 4 v 0 human up

A Gene Set from LINCS

GSE206931 WDR5 inhibition WIN 3 v 6 human up

A Gene Set from LINCS

GSE119978,GSE180930 0 V 4 CISPLATIN HUMAN UP

A Gene Set from LINCS

GSE56010 adenosine 4 v 1 human dn

A Gene Set from LINCS

GSE158834 ADIPOR2 knockout HEK293 12 v 13 human up

A Gene Set from LINCS

GSE157960 0 V 3 PROGESTERONE MOUSE DN

A Gene Set from LINCS

GSE152699 GSE152723 vemurafenib 3 v 2 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.